No Record Found
No Record Found
Sector
PharmaceuticalsOpen
₹2,370Prev. Close
₹2,366.45Turnover(Lac.)
₹381.02Day's High
₹2,440Day's Low
₹2,27352 Week's High
₹2,55052 Week's Low
₹682.25Book Value
₹465.19Face Value
₹10Mkt Cap (₹ Cr.)
1,269.32P/E
38.32EPS
61.76Divi. Yield
0.03No Record Found
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Equity Capital | 4.72 | 6.27 | 12.86 | 4.64 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 136.68 | 115.2 | 83.52 | 63.42 |
Net Worth | 141.4 | 121.47 | 96.38 | 68.06 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 133.89 | 112.77 | 58.06 | 56.69 |
yoy growth (%) | 18.72 | 94.2 | 2.41 | 33.96 |
Raw materials | -101.77 | -80.14 | -39.51 | -37.17 |
As % of sales | 76 | 71.06 | 68.04 | 65.57 |
Employee costs | -8.65 | -8.94 | -5.18 | -4.91 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 4.37 | 2.49 | 2.64 | 2.22 |
Depreciation | -2 | -1.87 | -1.28 | -1.13 |
Tax paid | -1.19 | -0.59 | -0.89 | -0.79 |
Working capital | 7.41 | 38.35 | 2.4 | 0.25 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 18.72 | 94.2 | 2.41 | 33.96 |
Op profit growth | 10.51 | 95.94 | 27.02 | -14.89 |
EBIT growth | 23.5 | 50.86 | 11.66 | 3.5 |
Net profit growth | 5.92 | 8.62 | 22.66 | 33.46 |
| Particulars (Rupees in Crores.) | Mar-2025 |
|---|---|
Gross Sales | 451.71 |
Excise Duty | 0 |
Net Sales | 451.71 |
Other Operating Income | 4.56 |
Other Income | 0 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,880 | 103.35 | 4,51,074.97 | 705.44 | 0.85 | 5,651.21 | 99.24 |
Divis Laboratories Ltd DIVISLAB | 6,761.1 | 69.77 | 1,79,485.96 | 598 | 0.44 | 2,578 | 578.26 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 4,406.15 | 66.77 | 1,49,124.14 | 577 | 0.14 | 2,547 | 249.82 |
Cipla Ltd CIPLA | 1,431.55 | 31.25 | 1,15,640.69 | 384.64 | 0.91 | 3,840.92 | 423.38 |
Dr Reddys Laboratories Ltd DRREDDY | 1,336.95 | 34.65 | 1,11,589.46 | -219.4 | 0.6 | 3,802.6 | 375.78 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairperson & Joint MD
Daulat N Medhora
Non Executive Director
Nariman B Medhora
Non Executive & Independent Director
Aspi N Raimalwala
Managing Director & CFO
Fredun N Medhora
Non Executive & Independent Director
Rohinton Kanga
Non Executive & Independent Director
Daisy Dsouza
Independent Director
Anshu Agarwal
Independent Director
Sonal Desai
26 Manoj Industrial Premises,
G D Ambedkar Marg Wadala,
Maharashtra - 400031
Tel: 91-22-40318111
Website: http://www.fredungroup.com
Email: business@fredungroup.com
9 ShivShakti Indl Es,
J R Boricha Marg, Lower Parel,
Mumbai - 400 011
Tel: 022- 23016761 / 2301
Website: www.purvashare.com
Email: support@purvashare.com
Summary
Incorporated in 1987 as a private limited company, Fredun Pharmaceuticals Limited (FPL) was converted into a public limited company in Mar.94. The Company was promoted by Nariman Medhora and Daulat N ...
Read More
Reports by Fredun Pharmaceuticals Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.